within Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA06_Brolucizumab;

model Brolucizumab
  extends Pharmacolibrary.Drugs.ATC.S.S01LA06;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>S01LA06</td></tr><td>route:</td><td>intravitreal</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Brolucizumab is a humanized single-chain antibody fragment (scFv) that targets vascular endothelial growth factor A (VEGF-A). It is used for the treatment of neovascular (wet) age-related macular degeneration (AMD) and is administered by intravitreal injection. Brolucizumab is approved and in clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult patients with neovascular (wet) age-related macular degeneration, receiving intravitreal injection of brolucizumab at the recommended clinical dose.</p><h4>References</h4><ol><li><p>Edington, M, et al., &amp; Chong, NV (2017). Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes. <i>Expert opinion on drug metabolism &amp; toxicology</i> 13(12) 1217–1224. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2017.1404987&quot;>10.1080/17425255.2017.1404987</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29134820/&quot;>https://pubmed.ncbi.nlm.nih.gov/29134820</a></p></li><li><p>Chakraborty, S, &amp; Sheth, JU (2022). Contralateral Effect following Intravitreal Brolucizumab Injection in Diabetic Macular Edema. <i>Case reports in ophthalmological medicine</i> 2022 3755249–None. DOI:<a href=&quot;https://doi.org/10.1155/2022/3755249&quot;>10.1155/2022/3755249</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35127189/&quot;>https://pubmed.ncbi.nlm.nih.gov/35127189</a></p></li><li><p>Kumar, A, et al., &amp; Anguita, R (2024). Perspectives on the currently available pharmacotherapy for wet macular degeneration. <i>Expert opinion on pharmacotherapy</i> 25(6) 755–767. DOI:<a href=&quot;https://doi.org/10.1080/14656566.2024.2354921&quot;>10.1080/14656566.2024.2354921</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38738427/&quot;>https://pubmed.ncbi.nlm.nih.gov/38738427</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Brolucizumab;
